MYGNMyriad Genetics, Inc.
4.360USD+9.14%Mkt Cap: 398.57M USDP/E: Last update: 2026-06-01

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides …

Indicators:|

Key Statistics

Company
Market Cap398.57M USD
Enterprise Value224.26M USD
Revenue (TTM)557.00M USD
Gross Profit576.60M USD
Net Income (TTM)-365.90M USD
Revenue/Share7.452 USD
Last Price4.360 USD
Fiscal Year EndDec 2025
MR QuarterDec 2020
Employees2.7K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS62855J1043
Valuation
P/E (Trailing)
P/E (Forward)24.81
PEG1.24
EV/EBITDA-2.00
EV/Revenue0.40
P/S0.67
P/B1.11
EPS (TTM)-4.31
EPS (Forward)0.16
52W Range
3.53016% of range8.590
52W High8.590 USD
52W Low3.530 USD
Profitability
Gross Margin69.93%
Oper. Margin-21.41%
EBITDA Margin-20.09%
Profit Margin-44.38%
ROE-99.43%
ROA-51.78%
Growth
Revenue Growth-20.80%
Earnings Growth
Cash Flow & Leverage
Operating CF1.80M USD
CapEx (TTM)27.40M USD
FCF Margin-8.27%
FCF Yield-11.56%
Net Debt-150.70M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.57
Current Ratio2.67
Quick Ratio1.65
Book Value/Sh3.574 USD
Cash/Share1.596 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split2:1
Split DateMar 26, 2009
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)6.250 USD
Target Range4.000 USD10.00 USD
# Analysts8
Ownership
Shares Out.94.45M
Float85.99M
Insiders3.26%
Institutions97.63%
Short Interest
Short Ratio5.3d
Short % Float9.04%
Short % Out.8.82%
Shares Short8.33M
Short (prev mo.)8.24M
Technical
SMA 504.477 (-2.6%)
SMA 2005.980 (-27.1%)
Beta1.64
S&P 52W Chg27.94%
Avg Vol (30d)1.53M
Avg Vol (10d)1.57M
Technical Indicators
RSI (14)45.7
MACD-0.1808
MACD Signal-0.2274
MACD Hist.+0.0466
BB Upper4.926 USD
BB Middle4.063 USD
BB Lower3.200 USD
BB Width42.48%
ATR (14)0.2693 USD
Vol Ratio (20d)0.62x